Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is being conducted in treatment-naive patients (no previous hepatitis C treatment)
to evaluate the safety of valopicitabine (NM283) alone and together with pegylated
interferon, a drug approved by the Food and Drug Administration for the treatment of
hepatitis C infection. This study is also evaluating the ability of valopicitabine to
decrease the amount of hepatitis C virus in the body. The results for patients taking
valopicitabine alone will be compared with the results for patients taking valopicitabine
together with pegylated interferon.